JATT Acquisition Corp. (JATT) Shareholders Approve Zura Bio Deal
by Marlena Haddad on 2023-03-16 at 4:47pm

JATT Acquisition Corp. (NYSE: JATT) announced this afternoon that its shareholders have approved its combination with clinical-stage biotechnology company Zura Bio.

A total of 4,907,863 ordinary shares, or 95.5% of JATT’s issued and outstanding ordinary shares, were present at today’s special meeting. The business combination was overwhelmingly approved as holders of 4,903,764 ordinary shares, or 99.9% of the votes cast at the meeting, voted in favor of the deal.

The parties expect to close the deal on March 20 after all closing conditions are satisfied or waived. The combined company’s ordinary shares and warrants are anticipated to begin trading on the Nasdaq on March 21 under the new ticker symbols, “ZURA” and “ZURAW”, respectively.

The SPAC disclosed last week that following the close, it will issue 2,500,000 new shares to its FPA investors. FPA investors Athanor Master Fund and affiliates already agreed to expand their FPA purchases last month to 3,000,000 shares at $10 per share and provide a binding redemption backstop of $15 million covering any redemptions in excess of 90%.

JATT initially announced its $215 million business combination with Zura Bio in June 2022. London-based Zura Bio is a clinical-stage firm developing novel medicines for immune disorders with an initial focus on alopecia.


ADVISORS

  • Raymond James & Associates, Inc. and its affiliates (together, “Raymond James”) is acting as the lead PIPE placement agent
  • Raymond James & Associates, Inc. is financial advisor to JATT in the transaction.
  • McDermott Will & Emery LLP is acting as legal counsel to Zura Bio.
  • Ogier is acting as legal counsel to Zura Bio.
  • Loeb & Loeb LLP and Simmons & Simmons are acting as legal counsel to JATT
  • Maples and Calder (Cayman) LLP are acting as Cayman Islands legal counsel to JATT.
  • Paul Hastings LLP is acting as legal counsel to Raymond James.

 

JATT Acquisition Corp. (JATT) Shareholders Approve Zura Bio Deal
Recent Posts
by Nicholas Alan Clayton on 2025-07-07 at 9:05am

Emmis Acquisition Corporation (NASDAQ:EMISU) has filed for a $100 million SPAC to take a look at the manufacturing sector after a few unique wrinkles in their IPO process. Initial investors are set to receive one right to a 1/10 share in each unit purchased and the SPAC will have 18 months to complete a business...

by Nicholas Alan Clayton on 2025-07-07 at 8:50am

Chenghe III (NASDAQ:CHEC.U) has filed for a $110 million SPAC to continue the team’s growing series while turning to a new underwriter. The new SPAC is offering investors a 1/2 warrant in each unit and no overfunding of the trust, but it will need to complete a business combination within 18 months of its IPO...

by Nicholas Alan Clayton on 2025-07-07 at 8:22am

At the SPAC of Dawn Futures sit slightly red as investors return from holidays of barbecues and fireworks to renewed concerns about where US President Donald Trump’s tariff policy might hamper trade. The latest shift produced a further one-month delay in most of the tariffs Trump has threatened to impose as his administration continues to...

by Kristi Marvin on 2025-07-05 at 10:02am

Terms Tracker for the Week Ending July 3, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. We’re heading into the July 4th holiday, so we’ll keep this week’s column short and to the point. But before you head to the beach,...

by Nicholas Alan Clayton on 2025-07-03 at 12:54pm

Crown PropTech (OTC:CPTKW) has entered into a definitive agreement to combine with rare earth mining firm Mkango Resources (TSX-V:MKA) at a pre-money equity value of $400 million. London-based Mkango is working to commercialize a chain of rare earth mining and refining facilities in Africa and Europe. The combined company is expected to trade on the...

logo

Copyright © 2025 SPACInsider, Inc. All Rights Reserved